Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 7;58(4):2004605.
doi: 10.1183/13993003.04605-2020. Print 2021 Oct.

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

William W Busse  1 , Pierluigi Paggiaro  2 , Xavier Muñoz  3 , Thomas B Casale  4 , Mario Castro  5 , G Walter Canonica  6 , Jo A Douglass  7   8 , Yuji Tohda  9 , Nadia Daizadeh  10 , Benjamin Ortiz  11 , Nami Pandit-Abid  12
Affiliations

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

William W Busse et al. Eur Respir J. .

Abstract

Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD

Trial registration: ClinicalTrials.gov NCT02414854.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: W.W. Busse is a consultant for AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Inc. and Sanofi; and is on the data safety monitoring board for Boston Scientific. Conflict of interest: P. Paggiaro received research grants and is an advisory board member for AstraZeneca, Chiesi, GlaxoSmithKline, Novartis and Sanofi. Conflict of interest: X. Muñoz is a speaker, scientific advisor for and has received clinical trial investigator fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Faes Farma, GlaxoSmithKline, Menarini, Mundipharma, Novartis and Teva. Conflict of interest: T.B. Casale received research support from American Lung Association, Genentech, NIH, Novartis, PCORI and Sanofi; is a consultant for AstraZeneca, Boehringer Ingelheim, Genentech, Novartis and Regeneron Pharmaceuticals, Inc.; is on the speakers bureau of Genentech. Conflict of interest: M. Castro received research support from American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis and Shionogi; is a consultant for Genentech, Novartis, sanofi-aventis and Teva; received speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi and Teva; received royalties from Elsevier. Conflict of interest: G.W. Canonica received speaker fees and is an advisory board member of ALK, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HAL Allergy, Menarini, Mundipharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Stallergenes Greer and Uriach. Conflict of interest: J.A. Douglass received research funding, speaker fees and is an advisory board member of AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. Conflict of interest: Y. Tohda is a consultant for AstraZeneca, Kyorin Pharmaceuticals and Sanofi. Conflict of interest: N. Daizadeh is an employee of and may hold stock and/or stock options in Sanofi. Conflict of interest: B. Ortiz is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: N. Pandit-Abid is an employee of and may hold stock and/or stock options in Sanofi.

Figures

FIGURE 1
FIGURE 1
a) Adjusted annualised severe exacerbation rate. b) Least squares (LS) mean difference in the change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) from baseline at week 12 between dupilumab and placebo by baseline patient demographic and disease characteristic subgroup. BMI: body mass index; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; ppb: parts per billion.
FIGURE 1
FIGURE 1
a) Adjusted annualised severe exacerbation rate. b) Least squares (LS) mean difference in the change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) from baseline at week 12 between dupilumab and placebo by baseline patient demographic and disease characteristic subgroup. BMI: body mass index; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; ppb: parts per billion.
See this image and copyright information in PMC

References

    1. Chung KF, Wenzel SE, Brozek JL, et al. . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. doi:10.1183/09031936.00202013 - DOI - PubMed
    1. Zein JG, Denson JL, Wechsler ME. Asthma over the adult life course: gender and hormonal influences. Clin Chest Med 2019; 40: 149–161. doi:10.1016/j.ccm.2018.10.009 - DOI - PubMed
    1. Khalid F, Holguin F. A review of obesity and asthma across the life span. J Asthma 2018; 55: 1286–1300. doi:10.1080/02770903.2018.1424187 - DOI - PubMed
    1. Harrison TW, Chanez P, Menzella F, et al. . Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 2021; 9: 260–274. doi:10.1016/S2213-2600(20)30414-8 - DOI - PubMed
    1. Sposato B, Scalese M, Latorre M, et al. . Effects of omalizumab in severe asthmatics across ages: a real life Italian experience. Respir Med 2016; 119: 141–149. doi:10.1016/j.rmed.2016.09.005 - DOI - PubMed

Publication types

Substances

Associated data